ATRC

AtriCure Inc

ATRC, USA

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

https://www.atricure.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ATRC
stock
ATRC

SG Americas Securities LLC Has $824,000 Position in AtriCure, Inc. $ATRC MarketBeat

Read more →
ATRC
stock
ATRC

(ATRC) Risk Channels and Responsive Allocation Stock Traders Daily

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$52.7778

Analyst Picks

Strong Buy

5

Buy

4

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

3.83

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-0.06 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-0.04 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

17.96 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.33

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 106.18% of the total shares of AtriCure Inc

1.

Vanguard Group Inc

(9.8714%)

since

2025/06/30

2.

BlackRock Inc

(8.0933%)

since

2025/06/30

3.

Wellington Management Company LLP

(7.9862%)

since

2025/06/30

4.

AllianceBernstein L.P.

(7.1902%)

since

2025/06/30

5.

Hood River Capital Management LLC

(6.1589%)

since

2025/06/30

6.

Macquarie Group Ltd

(5.0365%)

since

2025/06/30

7.

Champlain Investment Partners, LLC

(4.0577%)

since

2025/06/30

8.

Macquarie Small Cap Core I

(3.8015%)

since

2025/07/31

9.

Hood River Small-Cap Growth Instl

(3.2954%)

since

2025/06/30

10.

Vanguard Total Stock Mkt Idx Inv

(2.9397%)

since

2025/07/31

11.

Champlain Small Company Fund, LLC

(2.6846%)

since

2025/08/31

12.

State Street Corp

(2.5628%)

since

2025/06/30

13.

UBS Asset Mgmt Americas Inc

(2.4202%)

since

2025/06/30

14.

Neuberger Berman Group LLC

(2.3938%)

since

2025/06/30

15.

Geode Capital Management, LLC

(2.3777%)

since

2025/06/30

16.

iShares Russell 2000 ETF

(2.3473%)

since

2025/08/31

17.

Vanguard Small Cap Index

(2.2948%)

since

2025/07/31

18.

First Light Asset Management, LLC

(2.0425%)

since

2025/06/30

19.

GW&K Investment Management, LLC

(2.0288%)

since

2025/06/30

20.

AB Small Cap Growth A

(2.0258%)

since

2025/07/31

21.

Marshall Wace Asset Management Ltd

(2.0226%)

since

2025/06/30

22.

Nuveen, LLC

(1.8877%)

since

2025/06/30

23.

Dimensional Fund Advisors, Inc.

(1.6501%)

since

2025/06/30

24.

AB Discovery Growth A

(1.5516%)

since

2025/07/31

25.

BNP Paribas Investment Partners SA

(1.5202%)

since

2025/06/30

26.

Goldman Sachs Group Inc

(1.499%)

since

2025/06/30

27.

ING Investment Management LLC

(1.4293%)

since

2025/06/30

28.

Bank of America Corp

(1.4289%)

since

2025/06/30

29.

Champlain Small Company Adv

(1.3279%)

since

2025/06/30

30.

Vanguard Small Cap Growth Index Inv

(1.298%)

since

2025/07/31

31.

Old Westbury Small & Mid Cap Strategies

(1.2877%)

since

2025/04/30

32.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0712%)

since

2025/07/31

33.

Fidelity Small Cap Index

(0.9771%)

since

2025/06/30

34.

Wasatch Ultra Growth

(0.928%)

since

2025/06/30

35.

iShares Russell 2000 Growth ETF

(0.8556%)

since

2025/08/31

36.

Voya Small Cap Growth

(0.8328%)

since

2025/06/30

37.

Voya Small Cap Growth I

(0.8328%)

since

2025/07/31

38.

BNP Paribas Health Cr Innovtr Cl Cap

(0.7644%)

since

2025/07/31

39.

BNP Paribas US Small Cap ClassicC

(0.7594%)

since

2025/07/31

40.

Nuveen Quant Small Cap Equity R6

(0.6442%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.0991

Latest Release

Date

2025-09-30

EPS Actual

-0.01

EPS Estimate

-0.11

EPS Difference

0.1

Surprise Percent

90.9091%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Fair GARP(4)
Growth
Weak Growth Prospect(2.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(4.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.